Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy
04 oct. 2022 00h01 HE | Real Endpoints
FLORHAM PARK, N.J., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Real Endpoints, the leading market-access platform and advisory firm, announced a collaboration with bluebird bio, inc. (Nasdaq: BLUE), to...
Real Endpoints’ chairman, Roger Longman, named to PharmaVOICE 100
10 août 2021 09h45 HE | Real Endpoints
FLORHAM PARK, N.J., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Citing his creativity, entrepreneurialism, and leadership over the last 30 years, PharmaVOICE magazine has named Roger Longman, chairman of Real...
Real Endpoints Launches the First Turn-Key Platform for Value-Based Contracting
09 déc. 2020 10h45 HE | Real Endpoints
The RE Marketplace established with four founding health plans representing nearly 2.5 million lives. Each plan and its beneficiaries get immediate access to contracts for all biotech drugs in the...
Real Endpoints Strengthens and Broadens Access Capabilities and Reach with the Hiring of Key Executive
10 nov. 2020 14h30 HE | Real Endpoints
FLORHAM PARK, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Real Endpoints (RE), a leading boutique life science consultancy focused on market access, today announced it has hired Robert O’Brien as Vice...
Real Endpoints’ Susan Raiola Named to 2019 PharmaVoice 100
06 août 2019 09h00 HE | Real Endpoints
MADISON, N.J., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Real Endpoints (RE), an advisory and analytics firm entirely focused on enhancing appropriate access to healthcare innovation, announced today that...
Real Endpoints Appoints Jeff Berkowitz, CEO and Director
13 sept. 2018 11h14 HE | Real Endpoints
MADISON, N.J., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Real Endpoints (RE), a leader in the development and implementation of proprietary tools to strengthen pharmaceutical market access for an evolving...
Harvard Pilgrim and Illumina sign first-of-its-kind value-based contract
20 févr. 2018 10h00 HE | Real Endpoints
SAN DIEGO, WELLESLEY, Mass. and WESTPORT, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Illumina, Inc. and Harvard Pilgrim Health Care announced on February 1 a major new value-based contract (VBC) – one...
Real Endpoints Appoints Jane F. Barlow, MD, EVP and Chief Clinical Officer
17 juil. 2017 10h00 HE | Real Endpoints
WESTPORT, Conn., July 17, 2017 (GLOBE NEWSWIRE) -- Real Endpoints (RE), a data, analytics, and advisory company that helps payers and biopharma companies define the value and economic impact of new...
Survey finds variability in MS treatment preferences among individual patients, and among stakeholder groups
31 janv. 2017 17h16 HE | Real Endpoints
WESTPORT, CT--(Marketwired - January 31, 2017) - Real Endpoints, LLC (RE), a data and analytics firm focusing on assessing and quantifying pharmaceutical value, has just completed an extensive...
Move Over Gilead? AbbVie Could Bring Serious Competition to HCV Market
13 oct. 2014 12h25 HE | Real Endpoints
WESTPORT, CT--(Marketwired - Oct 13, 2014) - Gilead's Harvoni (sofosbuvir/ledipasvir combination) is the top overall scorer, according to RxScorecard, a drug-value assessment tool from Real...